Australia's Bioxyne jumps on strong quarterly results, upbeat outlook

BLS Pharmaceuticals

24/07/2025 05:28

** Shares of Bioxyne BXN.AX rise 12.8% to A$0.053, their highest since February 13

** Pharmaceutical co reports unaudited quarterly revenue of A$9.6 mln ($6.34 mln), up from A$3.1 mln year ago

** Says manufacture and supply agreement with Farmakem and Adrex in Germany will add significant strength to EU/UK operations

** Anticipates several additional contracts within EU/UK region as it continues to scale up operations throughout the region

** Expects to exceed FY25 revenue performance in FY26

** About 23.2 mln shares traded, 3.8x the 30-day avg

** YTD, stock up 96.3%

($1 = 1.5131 Australian dollars)

(Reporting by Ananya Verma in Bengaluru)

((ananya.verma@thomsonreuters.com;))